SCHEMBL434969

SCHEMBL434969

COc1ccc(C(OC(c2ccccc2)(c2ccccc2)c2ccc(OC)cc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA4 P22748 1/20 0.54
LTA4H P09960 2/20 0.52
KIF11 P52732 9/20 0.51
KCNH2 Q12809 1/20 0.51
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TRPA1 O75762 1/20 0.47
KMT2A Q03164 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136229 1.00 CA4 (0.54) CA4LTA4HKIF11KCNH2CA12
SCHEMBL430047 0.91 CA1 (0.58) CA4LTA4HCA12CA1CA2
SCHEMBL774134 0.87 CA4 (0.54) CA4LTA4HKIF11KCNH2CA12
SCHEMBL8784660 0.87 CA4 (0.54) CA4LTA4HKIF11KCNH2CA12
Bromide SCHEMBL31164184 0.85 CA4 (0.52) CA4LTA4HKIF11KCNH2CA12
Hydrochloric Acid SCHEMBL30389842 0.85 CA4 (0.52) CA4LTA4HKIF11KCNH2CA12
SCHEMBL8728589 0.83 KIF11 (0.56) CA4LTA4HKIF11KCNH2CA12
SCHEMBL3932304 0.83 CA4 (0.50) CA4LTA4HKIF11KCNH2CA12
SCHEMBL21738735 0.83 KIF11 (0.56) CA4LTA4HKIF11KCNH2CA12
SCHEMBL19620174 0.83 CA4 (0.50) CA4LTA4HKIF11KCNH2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236633-A1 SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES Roche Sequencing Solutions, Inc. (US) 2025-07-24 US claimed
EP-4499655-A1 SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES F. Hoffmann-La Roche AG (CH) 2025-02-05 EP claimed
WO-2023186842-A1 SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES F. HOFFMANN-LA ROCHE AG (CH) 2023-10-05 WO claimed
US-20180030065-A1 FLUORESCEIN POLYMER CONJUGATES ISI LIFE SCIENCES, INC. (US) 2018-02-01 US claimed
EP-3250197-A1 FLUORESCEIN POLYMER CONJUGATES Indicator Systems International, Inc. (US) 2017-12-06 EP claimed
WO-2016123244-A1 FLUORESCEIN POLYMER CONJUGATES INDICATOR SYSTEMS INTERNATIONAL, INC. (US) 2016-08-04 WO claimed
WO-2015053980-A1 PREPARATION OF ORGANOPHOSPHATE PEPTIDE ADDUCTS BATTELLE MEMORIAL INSTITUTE (US) 2015-04-16 WO claimed
US-20150099864-A1 PREPARATION OF ORGANOPHOSPHATE PEPTIDE ADDUCTS BATTELLE MEMORIAL INSTITUTE 2015-04-09 US claimed
WO-2008013427-A1 ORGANIC TFTS AND METHOD FOR FABRICATING THE SAME LG CHEM, LTD. (KR) 2008-01-31 WO claimed
JP-2006516295-A 2006-06-29 JP claimed
CN-1744918-A Polymeric reagents comprising a ketone or a related functional group NEKTAR THERAPEUTICS AL CORP (US) 2006-03-08 CN claimed
EP-1581260-A2 POLYMERIC REAGENTS COMPRISING A KETONE OR A RELATED FUNCTIONAL GROUP Nektar Therapeutics Al, Corporation (US) 2005-10-05 EP claimed
WO-2005058246-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 WO claimed
US-20050131224-A1 Method for preparing radiolabeled thymidine CTI PET SYSTEMS, INC. 2005-06-16 US claimed
WO-2004060406-A2 POLYMERIC REAGENTS COMPRISING A KETONE OR A RELATED FUNCTIONAL GROUP NEKTAR THERAPEUTICS AL, CORPORATION (US) 2004-07-22 WO claimed
US-12551570-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2026-02-17 US disclosed
US-12479927-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2025-11-25 US disclosed
EP-0016157-A4 7-0-(2,6-DIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)-DESMETHOXY-ADRIAMYCINONE. US COMMERCE (US) 1980-11-14 EP disclosed
EP-0016157-A1 7-0-(2,6-DIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)-DESMETHOXY-ADRIAMYCINONE THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) 1980-10-01 EP disclosed
WO-1980000305-A1 7-0-(2,6-DIDEOXY-A-L-LYXO-HEXOPYRANOSYL)-DESMETHOXYDAUNOMYCINONE,ADRIAMYCINONE,AND CARMINOMYCINONE US COMMERCE (US) 1980-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551570-B2 Compounds comprising cleavable linker and uses thereof FCGR2A, FCGR3B, FCGR1A CA4 192/4885LTA4H 2881/4885KIF11 3985/4885
US-20180030065-A1 FLUORESCEIN POLYMER CONJUGATES PFAS, CD44, FGB CA4 519/4885LTA4H 1504/4885KIF11 266/4885
US-12479927-B2 Compounds comprising cleavable linker and uses thereof VIP, ANTXR2, TNFRSF9 CA4 73/4885LTA4H 393/4885KIF11 3251/4885
US-20050131224-A1 Method for preparing radiolabeled thymidine TYMP, TYMS, DUT CA4 3875/4885LTA4H 1482/4885KIF11 650/4885
US-20250236633-A1 SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES PARG, PPA1, PGM2 CA4 1762/4885LTA4H 3409/4885KIF11 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.